Oakridge International Limited Overview
Oakridge International is an Australian micro-cap healthcare-technology company. In practice it is the listed holding company for JCT Healthcare Pty Ltd, an Adelaide-based designer, supplier, installer and maintainer of IP nurse call systems, assistive technology, real-time location systems (RTLS) and related software. JCT has operated for more than two decades. Its customers are hospitals, residential aged care, disability care, dementia care and supported independent living (SIL) providers, mainly in Australia. The listed entity has had several lives: a geothermal developer in Indonesia and India, then an IoT platform company (Xped), then a consolidated healthcare-technology business. In FY2026 it recorded revenue and other income of $3.45 million and its first statutory profit since FY2021 ($109,171). However, that profit depends on R&D tax incentives. With a market value near A$2 million, majority control by its CEO and a three-person board, Oakridge is an illiquid, founder-style turnaround story in a market where well-capitalised consolidators are active.
The company's own description
The FY2026 Annual Financial Report says the Group sells professional healthcare-technology equipment and solutions to healthcare facilities. It develops and distributes its own range of nurse call hardware and software for hospitals, aged care, disability care and supported independent living. The report says the Group continues to expand into assisted independent living technologies, using synergies with its legacy Internet of Things (IoT) platform. It also says the Group is looking at other emerging technology businesses focused on IoT and healthcare.
The FY2026 report adds two items:
-
Strategic planning on enterprise-grade reporting and AI-enabled capabilities for the NuCaMS platform.
-
Evaluation of a broader "connected clinical care" offering. This would combine nurse call workflow data with complementary consumables and non-invasive monitoring inputs, to support a more proactive model of care.
The company describes this opportunity as early-stage and subject to evaluation and approvals.
The language on adjacent sectors has changed over time. The FY2024 report listed renewable energy, energy storage, new-energy vehicles and energy-saving materials as exploratory interests. By FY2026 the stated adjacencies had narrowed to IoT, healthcare and AI-related care technology. This is a meaningful sharpening of focus.
Independent characterisation
| Revenue type (AUD) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Sale of goods, point in time (A$) | 883,160 | 661,028 | 2,004,339 | 2,908,722 |
| Projects and services, over time (A$) | 214,572 | 153,704 | 225,908 | 185,698 |
| Total revenue from contracts with customers (A$) | 1,097,732 | 814,732 | 2,230,247 | 3,094,420 |
| Goods share of customer revenue (%) | 80.5 | 81.1 | 89.9 | 94.0 |
Oakridge is, in substance, a single-business company. All of its revenue from customers comes from the Healthcare Technology segment (JCT Healthcare Pty Ltd) and all of it is earned in Australia (FY2026 Annual Financial Report, Notes 4 and 5).
The other reported segments are dormant or legacy:
Technology development: is the former Xped IoT/ADRC platform. It had no revenue and only $55,000 of consulting cost in FY2026.
Geothermal projects: comprises fully impaired Indonesian and Indian interests. Its only economic value is a contingent earn-out from KS Orka Renewables on the Sokoria project.
Unallocated: captures listed-company overheads.
Business model. JCT is a project-based systems integrator with its own product IP. It designs and specifies proprietary nurse call hardware (call points, pendants, annunciator displays, intercoms) and software (the NuCaMS platform, mobile apps, reporting and integrations). It procures and holds inventory, then delivers projects through programming, first-fix, component delivery, commissioning and installation. It also provides recurring 24/7 technical support, maintenance, networking and software development services. It sells directly and through a national network of channel partners (installers and integrators), which management has been actively expanding.
Revenue model mix. Revenue is overwhelmingly product-led and recognised at a point in time:
Source: FY2024 and FY2026 Annual Financial Reports, Note 5. The share row is an analyst calculation.
Subscription and licensing revenue are not separately reported. The legacy Bio SA royalty-linked messaging licence produced no royalties in FY2024–FY2026. The trend is notable: as revenue has scaled, the mix has moved further toward hardware. Services and projects fell to 6.0% of customer revenue in FY2026. This contrasts with listed peer Austco Healthcare, which is building a recurring software and maintenance layer (12% of its FY2026 revenue, per Austco's FY2026 results).
Value-chain position. JCT sits in the middle of the value chain. It owns product design and software IP and outsources component manufacturing. The FY2026 report refers to RTLS hardware moving into production and to "inventory in transit", implying imported components. It also handles installation, either directly or through partners. It does not own contract-manufacturing capacity.
Customer types and end-markets.
-
Public and private hospitals (acute care).
-
Residential aged care operators.
-
Disability care providers and SIL accommodation, including NDIS-funded participants and occupational-therapist-specified assistive technology.
-
Dementia care units.
-
Retirement and independent living villages.
Customers are typically facility operators, procuring directly or through builders and electrical integrators. No individual customer concentration data is disclosed.
Strategy
Stated strategic themes (paraphrased from the FY2024–FY2026 Annual Financial Reports)
-
Product leadership and standards compliance. Advance the healthcare product suite in line with the 2024 nurse call standard.
-
Channel-led national growth. Build new partner relationships and strengthen existing ones across aged care, disability, hospital and retirement living, while continuing direct sales.
-
Enterprise and cloud scale. Develop NuCaMS Enterprise with multi-site reporting, single sign-on and Azure cloud integration.
-
RTLS and assistive technology adjacency. Commercialise RTLS hardware and expand integrated SIL and assistive technology deployments.
-
AI and connected clinical care (exploratory). Plan AI-enabled reporting for NuCaMS and evaluate a connected clinical care offering combining workflow data, consumables and non-invasive monitoring.
-
Operational discipline. Adopt Zoho Books and inventory platforms, work toward ISO 9001:2015 and ISO 27001 readiness, and control expenses and working capital.
-
Capital and partnerships. Monitor overheads and cash flow, strengthen the capital base and seek strategic partners. FY2024 also referred to pursuing strategic acquisitions in healthcare.
Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Timing | Status / target | Source |
|---|---|---|---|
| RTLS enablement of the NuCaMS core platform | Completed by Dec 2025 quarter | Initial hardware production early 2026; call point and pendant work completed in FY2026 | Q2 FY2026 4C; FY2026 Annual Financial Report |
| NuCaMS Enterprise first-stage reporting | FY2026 | Completed and demonstrated; further reporting and integration features under way toward broader deployment | FY2026 Annual Financial Report |
| Azure cloud integration, SSO and authentication | FY2026 | Cloud-based integration with Microsoft Azure validated | FY2026 Annual Financial Report |
| AI-enabled capability planning for NuCaMS | FY2026 | Strategic planning stage | FY2026 Annual Financial Report |
| Connected clinical care offering | FY2026 | Under evaluation; early stage; may need board or regulatory approval | FY2026 Annual Financial Report |
| Zoho Books and inventory systems | FY2025–FY2026 | Adoption progressing | Q3 FY2026 4C; FY2026 Annual Financial Report |
| ISO 9001:2015 and ISO 27001 readiness | FY2026 | Readiness activities ongoing; certification not yet announced | FY2026 Annual Financial Report |
| Marketing and digital refresh | FY2026 | Website refresh and lead-generation work ongoing; ITAC Conference in Brisbane, May 2026 | FY2026 Annual Financial Report |
| Capital strengthening | 30 Jun 2026 | $349,996 option exercise by Montague (net $250,000 cash) | FY2026 Annual Financial Report; Q4 FY2026 4C |
ESG and sustainability commitments. None announced. Cost programs with targets. None with quantified targets.
Medium-term targets and guidance
The company gives no quantitative financial guidance or medium-term targets. Its only forward statement is that current channel activity and project conversion are expected to support revenue into FY2027 (FY2026 Annual Financial Report; Q4 FY2026 4C). The Q3 FY2026 update described the company as running "ahead of budget", but the budget itself was not disclosed.
Products & Services
All products sit in the Healthcare technology segment under the JCT brand. The company does not disclose pricing, unit volumes or per-product revenue. Launch years are given only where the company disclosed them.
Nurse call systems ("True IP Nurse Call")
| Product / component | Description and capabilities | Target customer | Latest version / status | Source |
|---|---|---|---|---|
| NuCaMS (Nurse Call Management System) | JCT's proprietary nurse call management software. It reports on call response times, call frequency, alarm types, duration, care time and compliance, with historical analysis and custom reports on request. It supports configurable clinical workflows and alerts (for example, a door opening at night). | Hospitals, aged care, disability care | Continuously enhanced. FY2026 work covered reporting, scalability, integration and performance. | jct.com.au FAQ; FY2026 Annual Financial Report |
| NuCaMS Enterprise | Multi-site, enterprise-scale version of NuCaMS, deployable on physical or cloud infrastructure. In FY2026 the company completed and demonstrated first-stage enterprise reporting and validated cloud integration with Microsoft Azure. Software development covered administration, authentication, reporting and single sign-on. AI-enabled capabilities are being planned. | Multi-facility operators (aged care groups, hospital networks) | Development ongoing toward broader deployment milestones (FY2026). | FY2026 Annual Financial Report; Q3 FY2026 4C summary |
| NuCaMS staff mobile app | Staff nurse call app for Android and Apple iOS. Customers cite its duress functionality. | Care staff | Mobile development ongoing (FY2026) | jct.com.au; FY2026 Annual Financial Report |
| Call points | Bedside and room call points, including RTLS-enabled call points completed in FY2026. | All care settings | RTLS call point work completed in FY2026 | FY2026 Annual Financial Report |
| Resident pendants | Wearable resident call pendants, including RTLS-enabled versions completed in FY2026. | Aged care, dementia, SIL | Completed FY2026 | FY2026 Annual Financial Report |
| Nurse Call Intercom points | Two-way voice points that let staff talk to residents anywhere in the building, including via phone. | Hospitals, aged care | In market | jct.com.au FAQ |
| LED and LCD annunciator display modules | Corridor and station displays showing active calls. Refined during FY2026. | Hospitals, aged care | Refined FY2026 | FY2026 Annual Financial Report |
| Wireless nurse call | Wireless system variants used in upgrades. Mentioned in FY2026 partner engagements. | Retrofit and upgrade sites | In market | FY2026 Annual Financial Report |
| Replacement servers | Server hardware and arrangements supplied to installed-base customers. | Installed base | Referenced in FY2026 delivery activity | FY2026 Annual Financial Report |
Standards alignment. The company says its product roadmap aligns with an evolving 2024 Australian nurse call standard. The FY2026 report cites it as "AS8311:2024". That exact designation could not be independently verified; it may refer to the Australian patient alarm standard series. Compliance with the current standard matters for tender eligibility.
Assistive Technology
| Offering | Description | Target customer | Notes / source |
|---|---|---|---|
| JCT Assistive Technology suite | Described as award-winning. Lets residents control everyday household items with a button press, while carers receive timely alerts. Includes a staff and client app built for assistive technology use. | Disability care, SIL, NDIS participants, independent living | jct.com.au. Interest from occupational therapists and NDIS participants rose significantly in FY2024 (FY2024 Annual Financial Report). |
| Integrated SIL deployments | Combined nurse call, assistive technology and environmental control packages for supported living accommodation. | SIL operators | Deployments expanded in FY2026 (FY2026 Annual Financial Report; Q4 FY2026 4C) |
| Independent living packages | Custom packages for individuals living at home. | Consumers and families | jct.com.au |
RTLS (Real-Time Location System) Positioning Technology
| Offering | Description | Status / source |
|---|---|---|
| JCT RTLS | Tracking of people and assets inside facilities, integrated with nurse call so call location and staff presence can be captured. | RTLS enablement of the core platform completed (Q2 FY2026). Initial hardware production set for early 2026 (Jan 2026 4C). RTLS call point and pendant work completed and specification materials prepared for market (FY2026 Annual Financial Report). RTLS deployments appear in partner engagements. |
CCTV, security and access control
JCT's website metadata describes "advanced CCTV & Security Solutions". GlobalData's company profile lists CCTV and access control services. No product-level detail or revenue is disclosed.
Services
| Service | Description | Source |
|---|---|---|
| 24/7 technical support | National hotline (1300 859 630) and support email | jct.com.au |
| Software development | Interface development, mobile platform design, reporting products, third-party integrations | jct.com.au |
| Scheduled reporting | Automated statistical call reports delivered to customer executives on a schedule | jct.com.au |
| Clinical workflow configuration | Custom alerts and escalations through the NuCaMS management engine | jct.com.au |
| Networking | Facility data networking, regardless of which healthcare technology is installed | jct.com.au |
| Maintenance | Servicing of hospital and aged care sites across rural and metropolitan Australia | jct.com.au |
Legacy / dormant technology (Technology development segment)
| Asset | Description | Status |
|---|---|---|
| ADRC (Auto Discovery Remote Control) IoT platform | Patented technology that lets a smartphone automatically discover and control embedded devices. Components included an infrastructure platform, ADRC daemon, ADRC proxy and "One Tap" provisioning. | No revenue FY2023–FY2026. Segment costs $10,000 (FY2024), $10,000 (FY2025), $55,000 (FY2026). Retained as a source of "synergies" for assisted living. |
| Jemsoft AI assets (acquired 2017) | Computer vision and AI technology | Current status not publicly disclosed |
| Web-based messaging software (Bio SA grant, 2012–13) | Messaging software licence developed with a $230,000 state grant | No royalties FY2024–FY2026; not expected to produce material royalties |
Financial Narrative
Sources. FY2023–FY2024: FY2024 Annual Financial Report. FY2025–FY2026: FY2026 Annual Financial Report. FY2022: FY2024 Annual Financial Report (five-year table, opening balances), with FY2022 customer revenue taken from TipRanks (an aggregator, labelled accordingly). Blank cells mean not publicly disclosed in the sources available.
Margins and growth (analyst calculations)
Revenue CAGR. Customer revenue grew at about 58% a year over FY2022–FY2026, from $496,860 to $3,094,420. The FY2022 base is from an aggregator.
Commentary.
Revenue inflection: Revenue roughly tripled between FY2024 and FY2026. Management attributes this to increased business development and channel-partner expansion (FY2025 and FY2026 Appendix 4E). The FY2024 dip (−25.8%) followed a lumpy FY2023. This volatility is typical of project-based nurse call revenue at small scale.
Gross margin compression, then recovery: Gross margin fell from 63.7% (FY2023) to 50.1% (FY2025), then recovered to 54.7% (FY2026). The decline is consistent with a mix shift toward hardware supply through channel partners, who keep installation margin, and with competitive pricing to win volume. The FY2026 recovery suggests some operating leverage in procurement. JCT's gross margin is close to Austco Healthcare's FY2026 gross margin of 53.4%.
Profit quality: The FY2026 statutory profit of $109,171 is less than the $349,527 R&D tax incentive recognised. Without the incentive, the group would have lost about $240,000. Every year from FY2023 to FY2026 shows an underlying loss. Still, the underlying loss has narrowed by about $950,000 from FY2024 to FY2026, which is the key positive trend.
Costs: Employee and contracting costs rose 30% in FY2026 to $939,522, below the 39% rise in customer revenue. Consulting fees fell from $180,000 to $60,000. Professional and legal fees remain elevated at $137,160 for a company of this size.
Balance sheet (A$, 30 June)
Short- and long-term debt split.
Bank debt: none. The Group had no undrawn facilities at 30 June 2026.
Bio SA loan ($32,548): shown as current on the balance sheet but as 1–5 years in the liquidity maturity table, a minor internal inconsistency.
Leases: $62,906, all due within 12 months at 30 June 2026. The corporate office lease expires 12 March 2027 and the JCT office lease expires 14 November 2026.
Contingent liability: the Bio SA loan balance of $288,109 is not recognised. It is payable only if JCT becomes insolvent or leaves South Australia.
Commentary.
Balance sheet scale: The balance sheet is tiny but unlevered. Cash fell from $1.73 million (FY2022) to $0.47 million (FY2025) before recovering to $0.64 million (FY2026). The recovery came from positive operating cash flow and a $250,000 net cash option exercise.
Inventory build: Inventory more than doubled in FY2026 to $795,724, and $102,827 of prepaid inventory sat in prepayments. This reflects management's stated build ahead of anticipated demand and RTLS hardware production. It ties up most of working capital.
Inventory as audit risk: Inventory valuation was the Key Audit Matter in both FY2024 and FY2026. The obsolescence provision was cut by $250,000 in FY2025, which was booked as a reversal through profit. FY2026 gross inventory was $986,513 against a provision of $190,789.
Tax losses: Unrecognised tax losses (tax-effected at 25%) were $10.42 million at 30 June 2026. That implies about $41.7 million of gross carried-forward losses. These are a latent asset whose usability depends on passing the continuity-of-ownership or similar-business tests.
Cash flow (A$)
Commentary.
First positive operating cash flow: FY2026 was the first year in the series with positive operating cash flow ($127,028). It was helped by $349,527 of R&D refunds; without the refund, operating cash flow would have been about −$222,000.
Lease-adjusted free cash flow: After lease principal, free cash flow remained negative at −$81,298.
Option exercise mechanics: Of the $349,996 recorded for Montague's option exercise, $99,996 was "expenses converted to shares". Net new cash was $250,000. During the year the Group drew and repaid $250,000 of borrowings, consistent with the $215,000 interest-free director-related advance disclosed at the half year. Investors should note the related-party funding dependence.
Ratios (analyst calculations; averages use opening and closing balances)
Commentary.
Returns: Returns turned positive in FY2026. Small denominators magnify the percentages: a ROIC of 15.3% on roughly $0.73 million of average invested capital means little in absolute terms.
Working capital: Working capital is the critical efficiency metric. The cash conversion cycle improved sharply in FY2025 (95.5 days) as inventory turned, then lengthened to 166.6 days in FY2026 because of the deliberate inventory build.
Leverage: Leverage is negligible and the Group is net cash. Net debt to EBITDA of −2.31x indicates a net cash position, so it is not a meaningful leverage measure.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership | Role |
|---|---|---|---|
Oakridge International Limited | Australia | Listed parent | Holding company, corporate costs |
JCT Healthcare Pty Ltd | Australia | 100% | Operating company: nurse call, assistive technology, RTLS |
Oakridge Healthcare Pty Ltd | Australia | 100% | Holding/intermediate (activities not separately disclosed) |
Oakridge Asia Holdings Pty Ltd | Australia | 100% | Legacy holding vehicle for geothermal interests (activities not separately disclosed) |
Osiris Energy Pty Ltd | Australia | 100% | Legacy energy vehicle; converted from public to proprietary company in FY2023 |
Revenue by Segment (AUD)
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Healthcare technology revenue (AUD) | 1,247,764 | 1,170,023 | 2,433,074 | 3,357,231 |
Technology development revenue (AUD) | 0 | 0 | 0 | 0 |
Geothermal projects revenue (AUD) | 0 | 0 | 0 | 0 |
Unallocated revenue (AUD) | 13,238 | 7,006 | 266 | 88,777 |
Total revenue and other income (AUD) | 1,261,002 | 1,177,029 | 2,433,340 | 3,446,008 |
Revenue by Segment (AUD) — Healthcare technology PBT
| Segment | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Healthcare technology PBT (AUD) | 428,983 | -97,172 | 563,822 | 671,218 |
Technology development PBT (AUD) | 0 | -10,000 | -10,000 | -55,000 |
Geothermal projects PBT (AUD) | -1,856 | 145,077 | 0 | 0 |
Unallocated PBT (AUD) | -543,239 | -799,153 | -761,715 | -507,047 |
Group PBT (AUD) | -116,112 | -761,248 | -207,627 | 109,171 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Healthcare technology PBT margin on segment revenue (%) | 34.4 | -8.3 | 23.2 | 20.0 |
Healthcare technology segment revenue YoY growth (%) | — | -6.2 | 108.0 | 38.0 |
Healthcare technology share of group revenue (%) | 99.0 | 99.4 | 100.0 | 97.4 |
Healthcare technology PBT excluding R&D incentive and one-offs (AUD) | -90,192 | -381,128 | 110,995 | 408,856 |
Income Statement (AUD) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from contracts with customers (AUD) | 496,860 | 1,097,732 | 814,732 | 2,230,247 | 3,094,420 |
R&D tax concession recognised (AUD) | — | 149,741 | 176,384 | 202,827 | 349,527 |
Total revenue and other income (AUD) | — | 1,261,002 | 1,177,029 | 2,433,340 | 3,446,008 |
Cost of sales (AUD) | — | 398,284 | 333,003 | 1,112,101 | 1,401,242 |
Gross profit on customer revenue (A$, derived) | — | 699,448 | 481,729 | 1,118,146 | 1,693,178 |
Employee and contracting expenses (AUD) | — | 576,058 | 632,834 | 724,267 | 939,522 |
Directors' remuneration (AUD) | — | 235,992 | 244,992 | 247,992 | 247,992 |
Operating income / EBIT excl. interest income (A$, derived) | — | -101,740 | -725,952 | -200,119 | 111,551 |
EBITDA (A$, derived) | — | -67,345 | -619,848 | -85,522 | 235,068 |
Finance costs (AUD) | — | 27,795 | 42,302 | 7,774 | 4,441 |
Profit before tax (AUD) | — | -116,112 | -761,248 | -207,627 | 109,171 |
Income tax benefit (AUD) | — | 0 | 0 | 78,832 | 0 |
Net profit attributable to owners (AUD) | -531,030 | -116,112 | -761,248 | -128,795 | 109,171 |
Underlying PBT excl. R&D incentive and one-offs (A$, derived) | — | -635,287 | -1,191,392 | -660,454 | -240,356 |
Basic and diluted EPS, recalculated (A cents) | -3.09 | -0.68 | -4.31 | -0.48 | 0.40 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Customer revenue YoY growth (%) | 120.9 | -25.8 | 173.7 | 38.7 |
Total revenue YoY growth (%) | — | -6.7 | 106.7 | 41.6 |
Gross margin on customer revenue (%) | 63.7 | 59.1 | 50.1 | 54.7 |
EBIT margin on total revenue (%) | -8.1 | -61.7 | -8.2 | 3.2 |
EBITDA margin on total revenue (%) | -5.3 | -52.7 | -3.5 | 6.8 |
Net margin on total revenue (%) | -9.2 | -64.7 | -5.3 | 3.2 |
R&D incentive as share of total revenue (%) | 11.9 | 15.0 | 8.3 | 10.1 |
Balance Sheet (AUD) and Share Count (number)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD) | — | 1,985,123 | 1,807,791 | 1,606,097 | 2,123,849 |
Cash and cash equivalents (AUD) | 1,725,273 | 1,091,900 | 961,575 | 468,939 | 637,641 |
Term deposits securing lease guarantees (AUD) | — | 48,448 | 64,100 | 61,948 | 61,948 |
Trade and other receivables (AUD) | — | 100,890 | 170,991 | 138,878 | 284,683 |
Inventory, net (AUD) | — | 441,242 | 305,688 | 380,757 | 795,724 |
Inventory obsolescence provision (AUD) | — | 440,789 | 440,789 | 190,789 | 190,789 |
Plant and equipment (AUD) | — | 40,578 | 41,354 | 64,873 | 144,085 |
Right-of-use assets (AUD) | — | 253,530 | 258,462 | 157,570 | 56,679 |
Goodwill and intangibles (AUD) | — | 0 | 0 | 0 | 0 |
Total current liabilities (AUD) | — | 546,538 | 586,895 | 625,406 | 737,693 |
Borrowings, Bio SA royalty loan (AUD) | — | 32,548 | 32,548 | 32,548 | 32,548 |
Lease liabilities (AUD) | — | 256,227 | 268,500 | 169,393 | 62,906 |
Total debt incl. leases (AUD) | — | 288,775 | 301,048 | 201,941 | 95,454 |
Net cash, cash minus debt incl. leases (AUD) | — | 803,125 | 660,527 | 266,998 | 542,187 |
Total liabilities (AUD) | — | 755,201 | 776,750 | 703,851 | 762,436 |
Total equity (AUD) | 1,346,034 | 1,229,922 | 1,031,041 | 902,246 | 1,361,413 |
Contributed equity (AUD) | 28,799,411 | 28,799,411 | 29,329,690 | 29,329,690 | 29,679,686 |
Accumulated losses (AUD) | 27,453,377 | 27,569,489 | 28,330,737 | 28,459,532 | 28,350,361 |
Working capital (A$, derived) | — | 1,144,477 | 921,080 | 758,248 | 1,185,392 |
Shares on issue (number) | 17,195,679 | 17,195,679 | 26,997,908 | 26,997,908 | 31,997,851 |
Cash Flow (AUD)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD) | — | 1,090,606 | 568,247 | 2,254,253 | 2,958,569 |
R&D incentives and grants received (AUD) | — | 281,242 | 176,384 | 202,827 | 349,527 |
Payments to suppliers and employees (AUD) | — | 1,796,735 | 1,272,318 | 2,804,492 | 3,178,688 |
Operating cash flow (AUD) | — | -414,602 | -530,672 | -358,457 | 127,028 |
Capital expenditure, plant and equipment (AUD) | — | 28,461 | 16,685 | 37,224 | 101,838 |
Free cash flow, OCF minus capex (A$, derived) | — | -443,063 | -547,357 | -395,681 | 25,190 |
Lease principal paid (AUD) | — | 20,352 | 82,968 | 99,107 | 106,488 |
FCF after lease principal (A$, derived) | — | -463,415 | -630,325 | -494,788 | -81,298 |
Equity issued, gross (AUD) | — | 0 | 500,000 | 0 | 349,996 |
Dividends paid (AUD) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Return on equity (%) | -9.0 | -67.3 | -13.3 | 9.6 |
Return on assets (%) | — | -40.1 | -7.5 | 5.9 |
ROIC, EBIT over equity plus debt minus cash (%) | — | -182.1 | -39.8 | 15.3 |
Current ratio (x) | 3.09 | 2.57 | 2.21 | 2.61 |
Debt to equity incl. leases (x) | 0.23 | 0.29 | 0.22 | 0.07 |
Net debt to EBITDA (x) | — | — | — | -2.31 |
Interest coverage, EBIT over finance costs (x) | -3.66 | -17.16 | -25.74 | 25.12 |
Asset turnover, customer revenue over average assets (x) | — | 0.43 | 1.31 | 1.66 |
Days sales outstanding, year-end (days) | 30.6 | 70.5 | 22.7 | 33.6 |
Days inventory outstanding, year-end (days) | 404.4 | 335.1 | 125.0 | 207.3 |
Days payables outstanding, year-end (days) | 156.7 | 134.0 | 52.2 | 74.3 |
Cash conversion cycle (days) | 278.3 | 271.6 | 95.5 | 166.6 |
Revenue by Region (AUD) and Region Margins & Growth (%)
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia customer revenue (AUD) | 1,097,732 | 814,732 | 2,230,247 | 3,094,420 |
Rest of world customer revenue (AUD) | 0 | 0 | 0 | 0 |
Australia YoY growth (%) | — | -25.8 | 173.7 | 38.7 |
Australia share of customer revenue (%) | 100 | 100 | 100 | 100 |
Share Price and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.073 | 0.072 | 0.071 | 0.060 | 0.072 |
Shares on issue at 30 June (millions) | 17.20 | 17.20 | 27.00 | 27.00 | 32.00 |
Market capitalisation at 30 June (AUD Mn) | 1.26 | 1.24 | 1.92 | 1.62 | 2.30 |
Return period (to 30 Jun 2026)
| Return period (to 30 Jun 2026) | Return (%) | Basis |
|---|---|---|
1-year | 20.0 | $0.060 to $0.072 |
3-year | 0.0 | $0.072 to $0.072 |
5-year | -64.0 | $0.001 pre-consolidation at 30 Jun 2021, equal to $0.20 after the 200:1 consolidation, to $0.072 |
Valuation Multiples
| Multiple | Oakridge | Note |
|---|---|---|
Market cap (AUD Mn) | 2.05 | 31,997,851 shares |
Enterprise value (AUD Mn) | About 1.51 | Market cap − cash $0.64m + debt incl. leases $0.10m |
P/E (x) | About 18.8 | On statutory PAT of $109,171. Kalkine shows a trailing P/E of 7.10 on a different TTM basis; the discrepancy is noted. |
EV/EBITDA (x) | About 6.4 | On derived EBITDA of $235,068, which includes the R&D incentive |
EV/Sales (x) | About 0.49 | On customer revenue |
P/B (x) | About 1.5 | Equity $1.36m |
Price/NTA (x) | About 1.6 | NTA 4.08 cents per share |
Analyst Conclusions
Management guidance
There is no quantitative guidance. Management expects current channel activity, qualified opportunities and project conversion to support revenue into FY2027. It will continue to monitor overheads and cash flow, strengthen the capital base, seek strategic partners and assess complementary product, technology and AI opportunities (FY2026 Annual Financial Report; Q4 FY2026 4C).
Consensus expectations
None. The company has no analyst coverage.
Bull case
-
Operating leverage is visible. Customer revenue rose 39% in FY2026 while the unallocated cost base fell 33% (to $507,047). If JCT grows another 25–35% at a gross margin of 54–55%, the company could reach underlying profitability excluding R&D incentives within one to two years. That would release value from the $10.42 million tax-effected loss pool.
-
RTLS and NuCaMS Enterprise raise deal value and recurrence. Completed RTLS call points and pendants, validated Azure integration and multi-site reporting give the installed base a clear upgrade path. This could help reverse the fall in the services share toward Austco-style recurring revenue.
-
Strategic value floor. With an enterprise value of about $1.5 million, Oakridge trades near or below what a scale consolidator just paid for a South Australian nurse call peer ($2.88 million). A controlling shareholder who has kept investing equity is well placed to negotiate a sale or merger.
Bear case
-
Low-quality earnings. FY2026 profit is entirely the R&D incentive ($349,527 against PBT of $109,171). The underlying business still loses about $240,000 a year after head-office costs, and free cash flow after leases was −$81,298 even in a record year.
-
Squeezed by consolidation. Austco has 30 times the revenue, A$16.3 million of cash and an active acquisition program in Australia, including OAK's home state. This threatens OAK's channel partners, tender competitiveness and pricing power.
-
Governance and minority-holder risk. A CEO with a 52.81% stake, a combined Chair and CEO role, a three-person board, related-party consulting and funding arrangements, and a six-year unquantified Teko contingent liability. Minority holders have little influence, and the register is so illiquid that most holders own unmarketable parcels.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| By 31 Oct 2026 | Q1 FY2027 Appendix 4C: customer receipts against the $770,000 Q4 FY2026 run-rate, and inventory drawdown |
| Nov 2026 | 2026 AGM: board composition, remuneration resolutions, any capital-raising mandates |
| 13 Nov 2026 | Expiry of 306,480 employee options ($0.10) |
| 14 Nov 2026 | JCT office lease expiry: renewal terms, and whether JCT stays in South Australia (Bio SA contingency trigger) |
| 19 Dec 2026 | Expiry of 599,970 Unerkov-associated options ($0.10) |
| Late Jan 2027 | Q2 FY2027 4C: RTLS hardware revenue contribution |
| Feb 2027 | H1 FY2027 interim results: underlying profitability excluding R&D incentive |
| 12 Mar 2027 | Corporate office lease expiry: opportunity to cut overhead |
| Ongoing | ISO 27001 / ISO 9001 certification announcements; any connected clinical care or AI transaction; KS Orka further NOIDs; Teko SPA resolution; Austco consolidation moves; FY2026 R&D incentive claim size (received in FY2027) |
Analyst verdict
Oakridge International is a holding company that has finally become an operating company. After a decade of reinventions — geothermal developer, IoT platform, AI acquirer — almost all of the residual value now sits in JCT Healthcare, a two-decade-old Adelaide nurse call and assistive technology specialist. On the evidence of the FY2025 and FY2026 accounts, JCT is gaining commercial traction. Customer revenue nearly quadrupled between FY2024 and FY2026 to $3.09 million. Gross margins of about 55% match the regional market leader. The operating segment earns a genuine underlying profit before head-office costs.
The problem is everything above the operating line. A listed-company overhead of roughly half a million dollars, plus a profit that rests entirely on R&D tax refunds, means FY2026's first full-year profit since FY2021 is a milestone of trajectory, not of quality. Working capital is stretched by a doubled inventory balance, and the company has twice in three years turned to its controlling shareholder for funding. Governance is concentrated to a degree most institutional investors would not accept.
Strategically, the clock is ticking. Austco Healthcare is consolidating the Australian market with a strong balance sheet, and its August 2026 purchase of a South Australian nurse call business suggests small independents are more valuable inside a platform than alone. Organic progress on RTLS and NuCaMS Enterprise is real but early, and the "connected clinical care" and AI ideas are not yet business plans.
Our assessment is that Oakridge is a speculative, illiquid special situation. Its fundamentals are improving and its valuation is low (EV of about $1.5 million, about 0.5 times sales). Upside is most likely to come from a strategic transaction led by the controlling shareholder, or from two to three more quarters showing profitability excluding R&D incentives. Minority investors face significant liquidity, governance and execution risk and should size any exposure accordingly.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Age | FY2026 total remuneration (AUD) |
|---|---|---|---|---|---|---|
Con Unerkov | Executive Chairman and CEO (also described as interim CFO by data providers); member of the Nomination and Remuneration Committee | Non-executive Chairman 31 Dec 2019; CEO 3 Feb 2021 | More than 25 years as an executive and CEO in private and public companies, focused on structuring, M&A and corporate finance. The FY2026 report describes him as Chairman and CEO of Integrated Media Technology Limited (NASDAQ: IMTE). The FY2024 report described him as a former chairman of IMTE and chairman of a clean-energy charging company; this inconsistency is noted. | — | About 57 (born 1969, per Yahoo Finance) | 199,992 |
Peter Whelan | Independent non-executive director; Audit Committee Chair; member of the Nomination and Remuneration Committee | 29 Jan 2021 | Chartered Accountant with more than 50 years' experience. Former Managing Partner and Chairman of Partners at a mid-tier South Australian accounting firm (corporate advisory and audit). Extensive auditing in aged care and retirement living. Charity board and finance committee member. | — | — | 24,000 |
Wally Pastuch | Non-executive director; Nomination and Remuneration Committee Chair; Audit Committee member | 3 Mar 2025 | More than 40 years across the automotive, insurance and IT industries. Implemented inventory systems at Ford Australia, was Regional Manager VIC/TAS at Mitsubishi Motors Australia, and developed insurance products at an IAG affiliate. | — | — | 24,000 |
Julie Edwards | Company Secretary | — | Accounting and finance management experience. B.Com, CPA Australia member, CPA Public Practice Certificate, registered Tax Agent. | B.Com | — | Not disclosed (not KMP) |
John Schultz | Founder and Head of Engineering (per Yahoo Finance; Xped co-founder) | — | Xped co-founder | — | About 61 (born 1965) | — |
Christopher Wood | Founder and CTO (per Yahoo Finance; Xped co-founder) | — | Xped co-founder | — | About 64 (born 1962) | 136,970 (per Yahoo Finance; year unspecified) |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Con Unerkov total remuneration (AUD) | 201,867 | 221,231 | 199,992 | 199,992 |
Peter Whelan fees (AUD) | 18,000 | 22,500 | 24,000 | 24,000 |
Elvis Diao fees (AUD) | 18,000 | 22,500 | 16,000 | 0 |
Wally Pastuch fees (AUD) | 0 | 0 | 8,000 | 24,000 |
Total KMP compensation (AUD) | 237,867 | 266,231 | 247,992 | 247,992 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Dec 2019 | Con Unerkov appointed non-executive Chairman | Linked to the Teko International placement |
24 Apr 2020 | Elvis Diao appointed NED | Greater China investor-relations background |
29 Jan 2021 | Peter Whelan appointed NED | Brought audit and aged-care sector expertise |
3 Feb 2021 | Unerkov becomes CEO, remaining Chairman | Restructuring before the Oakridge rebrand |
FY2025 (before Mar 2025) | Elvis Diao departs | Received $16,000 in FY2025, consistent with about eight months of service |
3 Mar 2025 | Wally Pastuch appointed NED | Systems and inventory management background |
Major Shareholders
| Rank | Holder | Shares | % of issued capital |
|---|---|---|---|
| 1 | Montague Capital Pty Ltd (Unerkov-associated) | 16,898,439 | 52.81 |
| 2 | Teko International Limited | 3,125,000 | 9.77 |
| 3 | Aliton Pty Ltd (Bell Family Super Fund A/C) | 1,674,309 | 5.23 |
| 4 | Heuresy Labs LLC | 1,000,000 | 3.13 |
| 5 | Mr Gabriel Govinda | 719,944 | 2.25 |
| 6 | JK Group Australia Pty Ltd (JK Family A/C) | 701,441 | 2.19 |
| 7 | Aerobotics Pty Ltd | 370,000 | 1.16 |
| 8 | BNP Paribas Nominees Pty Ltd (Clearstream) | 347,921 | 1.09 |
| 9 | Alanticx Technologies Pty Ltd (Alanticx A/C) | 222,084 | 0.69 |
| 10 | Aliton Pty Ltd | 220,013 | 0.69 |
Competitive Landscape
Key Competitors
| Competitor | Ownership / listing | Relevant offering | Scale / revenue | Positioning vs OAK | Source |
|---|---|---|---|---|---|
Austco Healthcare (Tacera, Pulse Mobile) | ASX: AHC | IP nurse call, clinical workflow, RTLS, mobile | FY2026 revenue A$94.2m; EBITDA A$14.9m; NPAT A$9.0m; more than 5,000 facilities in 60+ countries | About 30 times OAK's revenue; acquisitive; debt-free with A$16.3m cash | Austco FY2026 results |
Ascom | SIX Swiss Exchange | Nurse call, mobility, clinical alarm management; acquired GE Healthcare's nurse call unit | — | Global hospital-focused player | Mobile World Live (historical) |
Rauland (AMETEK) | NYSE: AME subsidiary | Responder nurse call | Not disclosed separately | Mainly US hospitals; limited Australian aged-care overlap | General industry knowledge |
Baxter / Hillrom (Voalte, NaviCare) | NYSE: BAX | Nurse call, care communications | Not disclosed separately | Acute hospital focus | General industry knowledge |
Stryker (Vocera) | NYSE: SYK | Clinical communications | Not disclosed separately | Hospital mobility and communications | General industry knowledge |
Advance Care | Private (Australia, founded 2000) | Advance Care nurse call system; branch and reseller network | — | Closest like-for-like domestic aged care competitor; claims many major acute and aged care operators | MedicalSearch listing |
Medical Communications Systems Pty Ltd | Acquired by Austco on 13 Aug 2026 (South Australia) | Nurse call | Acquisition price about A$2.88m | Former local peer, now part of the scale player | Austco FY2026 results |
Teknocorp, Amentco, G&S Technologies | Acquired by Austco | Nurse call and security integration | — | Consolidated into Austco | Austco FY2026 results |
Tunstall | Private (UK) | Telecare, aged care alarms | — | Independent living and telecare overlap | General industry knowledge |
Critical Alert Systems (with Intego) | Private (US) | Nurse call and workflow | — | US-focused | PRNewswire, 2012 |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Oakridge (FY2026) | Austco Healthcare (FY2026) |
|---|---|---|
Revenue (AUD Mn) | 3.09 (customer); 3.45 (incl. other income) | 94.2 |
Revenue growth (%) | 38.7 (customer) | 15.8 |
Gross margin (%) | 54.7 | 53.4 |
EBITDA margin (%) | 6.8 (incl. R&D incentive) | 15.8 |
Net margin (%) | 3.2 | 9.6 (derived: 9.0/94.2) |
Recurring software and maintenance share (%) | About 6 (projects and services, over time) | 12 |
Cash (AUD Mn) | 0.64 | 16.3 |
Recent Developments
Items such as product launches with named customers, contract wins with values, litigation and layoffs were not publicly disclosed. The register above lists every identifiable development in the period.



